Rib-X Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
New Haven, Connecticut. November 4, 2008 — Rib-X Pharmaceuticals, Inc.,
a development stage company focused on the discovery, development and commercialization of
novel antibiotics for the treatment of antibiotic resistant infections, announced today that
Susan Froshauer, Ph.D., President and Chief Executive Officer, is scheduled to present at the
Rodman & Renshaw 10th Annual Healthcare Conference on Monday, November 10, 2008 at 2:00pm EST.
The conference will be held from November 10 — 12, 2008 at the Palace Hotel, New York, New York.
About Rib-X Pharmaceuticals, Inc.
Rib-X Pharmaceuticals, Inc. is a product driven small molecule drug discovery and development
company focused on the structure based design of new classes of antibiotics. The Company's
underlying drug discovery engine capitalizes on its proprietary high-resolution crystal
structure of the ribosome, which performs an essential role in protein synthesis. Many known,
commercially valuable antibiotics exert their effects by binding to the bacterial ribosome. The
Company's integrated research strategy, which combines state-of-the-art, proprietary computational
analysis, X-ray crystallography, medicinal chemistry, microbiology and biochemistry, allows it
to rapidly synthesize new agents designed to avoid typical antibiotic resistance mechanisms.
Rib-X's iterative intelligent engine has yielded several distinctive new antibiotics that can
be used for the treatment of either community or hospital acquired infections. Radezolid (RX-1741),
an oxazolidinone, is an oral/IV agent for treatment of serious Gram-positive infections.
The
Rχ-04
discovery program is developing novel classes of antibiotics active against multi drug
resistant Gram-negative bacteria and the
Rχ-02
discovery program is focused on developing an IV/oral
macrolide active against methicillin resistant
S. aureus,
multidrug resistant
Streptococcus pneumoniae
and
S. pyogenes.
Additionally, Rib-X is developing delafloxacin, (RX-3341), an anionic fluoroquinolone active
against a broad spectrum of bacteria, including quinolone resistant Gram-positive bacteria and MRSA.
Both radezolid and delafloxacin are currently in Phase 2 clinical trials.
| Media/Investor Contact Information |
|---|
|
Gina Nugent
The Yates Network 617.460.3579 gina@theyatesnetwork.com |